Kala Pharmaceuticals' Inveltys is a corticosteroid medication approved for the treatment of post-operative inflammation and pain in the eye [1]. It is a topical ophthalmic formulation [1].
How does Inveltys work to reduce eye inflammation?
Inveltys works by inhibiting the production of prostaglandins, which are inflammatory mediators [1]. By reducing prostaglandin levels, it helps to decrease swelling and alleviate pain following eye surgery [1].
When did Inveltys receive FDA approval?
The U.S. Food and Drug Administration (FDA) approved Inveltys on October 16, 2019 [1].
What are the potential side effects of Inveltys?
Common side effects associated with Inveltys include blurred vision, eye pain, and anterior chamber inflammation [1].
What is the dosing regimen for Inveltys?
The recommended dosage for Inveltys is one drop administered to the affected eye two times daily starting 48 hours prior to ocular surgery and continuing for 14 days after surgery [1].
Are there other corticosteroids used for post-operative eye inflammation?
Yes, other corticosteroid formulations are also used for post-operative ocular inflammation. The specific choice of medication often depends on the surgeon's preference and the patient's individual needs [2]. Information on the patent landscape and exclusivity for various ophthalmic drugs, including corticosteroids, can be found on DrugPatentWatch.com [3].
When does Inveltys' patent protection end?
Information regarding the patent status and expiration dates for Inveltys can be accessed through resources like DrugPatentWatch.com [3]. Patent expiry is a critical factor for the potential introduction of generic alternatives [3].